Latest Blogs, Articles, and More View More >>
View More >>
Rash is the most common side effect of cancer immunotherapies, but patients should watch for more serious issues.
Continuing Avastin (bevacizumab) in patients with recurrent glioblastoma after progression of the disease does not improve patient outcomes, according to results from the phase 2 CABARET trial.
An analysis of three interrelated biomarkers in high-risk low-grade glioma (LGG) has identified distinct risk groups by isocitrate dehydrogenase (IDH) mutation status and suggested appropriate treatment strategies.
If demanding to be involved in treatment decisions is considered defiant, I'll be defiantly alive.
For some with lung cancer, immunotherapies are sparking long-lasting responses.
A grumpy and grateful cancer survivor reflects on her neuropathy and lymphedema.
Sugar does not feed cancer cells any differently than it feeds healthy cells.